@article {Kim19005975, author = {Mimi S. Kim and Christina M. Koppin and Pankhuri Mohan and Fariba Goodarzian and Heather M. Ross and Mitchell E. Geffner and Roger De Filippo and Paul Kokorowski}, title = {Absence of Testicular Adrenal Rest Tumors in Newborns, Infants, and Toddlers with Classical Congenital Adrenal Hyperplasia}, elocation-id = {19005975}, year = {2019}, doi = {10.1101/19005975}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {INTRODUCTION Testicular adrenal rest tumors (TART) are a known consequence for males with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. TART are associated with potential infertility in adults. However, little is known about TART in very young males with CAH.OBJECTIVE We assessed the prevalence of TART in newborn, infant, and toddler males with classical CAH via scrotal ultrasound.METHODS Males with CAH had scrotal ultrasounds during the first 4 years of life, evaluating testes for morphology, blood flow, and presence of TART. Newborn screen 17-hydroxyprogesterone (17-OHP) and serum 17-OHP at the time of ultrasound were recorded. Bone ages were considered very advanced if >= 2SD above chronological age.RESULTS Thirty-one ultrasounds in 16 males were performed. An initial ultrasound was obtained in four newborns at diagnosis (6.8 {\textpm}2.1 days), six infants (2.2 {\textpm}0.9 months), and six toddlers (2.4 {\textpm}0.9 years). Eleven males had at least one repeat ultrasound. A large proportion (11/16) were in poor hormonal control with an elevated 17-OHP (325 {\textpm}298 nmol/L). One infant was in very poor hormonal control (17-OHP 447 nmol/L) at initial ultrasound, and two toddlers had advanced bone ages (+3.2 and +4.5 SD) representing exposure to postnatal androgens. However, no TART were detected in any subjects.CONCLUSIONS TART were not found in males up to 4 years of age with classical CAH despite settings with expected high ACTH drive. Further research into the occurrence of TART in CAH may elucidate factors which contribute to the detection and individual predisposition to TART.Competing Interest StatementMitchell E. Geffner serves as an advisor to Daiichi Sankyo, Novo Nordisk, Nutrition \& Growth Solutions, Pfizer, and Spruce Biosciences; on data safety monitoring boards for Ascendis and Tolmar; and receives royalties from McGraw-Hill and UpToDate.Funding StatementThis work was supported by CARES Foundation (MSK and MEG) and the Abell Foundation (MEG). The writing of this paper was funded by K23 HD084735-01A1 (MSK).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData is available under IRB approved data-sharing with the PI.}, URL = {https://www.medrxiv.org/content/early/2019/09/11/19005975}, eprint = {https://www.medrxiv.org/content/early/2019/09/11/19005975.full.pdf}, journal = {medRxiv} }